Cochrane · systematic review · CD003748
Cilostazol for intermittent claudication
Brown, T, Forster, RB, Cleanthis, M, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 5 · 35.7%Low 5 · 35.7%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cilostazol compared with placebo for intermittent claudication
Population: intermittent claudication
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Initial claudication distance (change in metres) Cilostazol vs placebo | no estimate extracted | 6 studies · 1722 participants | Low Downgraded: risk of bias |
Quality of life (change in points/ percentage; COM, SF‐36, VascuQol, WIQ) Cilostazol vs placebo | no estimate extracted | 4 studies · 1163 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Absolute claudication distance (change in metres) Cilostazol vs placebo | no estimate extracted | 8 studies · 2360 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Arterial revascularisation (number of cases) Cilostazol vs placebo | OR 0.16 [0.01, 4.07] | 1 study · 516 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Amputation (number of cases) Cilostazol vs placebo | OR 0.16 [0.01, 4.07] | 1 study · 516 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Adverse event related to study medication ‐ headache (number of cases) Cilostazol vs placebo | OR 2.83 [2.26, 3.55] | 8 studies · 2584 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Cardiovascular event (number of cases) Cilostazol vs placebo | OR 1.5 [0.51, 4.47] | 2 studies · 692 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Cilostazol compared with pentoxifylline for intermittent claudication
Population: intermittent claudication
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Initial claudication distance (change in meters) Cilostazol vs pentoxifylline | no estimate extracted | 1 study · 417 participants | Low Downgraded: imprecision |
Quality of life (change in points, SF‐36, WIQ) Cilostazol vs pentoxifylline | no estimate extracted | 1 study · 317 participants | Very low Downgraded: imprecision, inconsistency, publication bias |
Absolute claudication distance (change in metres) Cilostazol vs pentoxifylline | no estimate extracted | 2 studies · 866 participants | Very low Downgraded: imprecision, inconsistency, publication bias |
Arterial revascularisation Cilostazol vs pentoxifylline | no estimate extracted | NR | No studies |
Amputation Cilostazol vs pentoxifylline | no estimate extracted | NR | No studies |
Adverse event related to study medication ‐ headache (number of cases) Cilostazol vs pentoxifylline | OR 2.2 [1.16, 4.17] | 2 studies · 982 participants | Low Downgraded: imprecision, inconsistency, publication bias |
Cardiovascular event Cilostazol vs pentoxifylline | no estimate extracted | NR | No studies |